Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Key Inclusion Criteria:

- Must have a diagnosis of CLE, either chronic (eg, discoid) or subacute CLE per
investigator evaluation, with the following:

- Moderately-to-severely active CLE (CLASI activity score ≥ 10) at screening and
Day 1

- Prior intolerance or inadequate response to at least one of the listed
medications for the treatment of CLE

- Stable dose (defined as no change in prescription for at least 28 days prior to Day 1)
of antimalarials and/or topical or oral corticosteroids is permitted during the study.
Individuals who are not planning to continue these medications during the study must
have discontinued them at least 28 days prior to Day 1

Key Exclusion Criteria:

- Use of prohibited concomitant medications per study protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.